Distinguish Semax, amidated and N-acetyl forms, match the sequence to the report, and check which research applies to a product.
Semax, Semax amidate and N-acetyl Semax amidate can describe different chemical forms. Before comparing research products, check the full peptide sequence, both end groups and the salt form. A shared seven-amino-acid sequence does not make their experimental results interchangeable.
This guide helps you compare a product description with its laboratory documents and cited research. Research-only vials and sprays should not be used as personal treatments.
The parent Semax sequence is Met-Glu-His-Phe-Pro-Gly-Pro, often shortened to MEHFPGP. FDA's 2026 chemistry review identifies the parent with a free amino end and a carboxylic-acid end. N-terminal acetylation and C-terminal amidation modify different ends; a product can have either change or both. FDA chemistry review, pages 8 to 11, GenScript peptide modification guide.
| Name used precisely | Sequence notation | What changes |
|---|---|---|
| Semax, parent peptide | H-MEHFPGP-OH | Neither end is capped |
| N-acetyl Semax | Ac-MEHFPGP-OH | An acetyl group is attached at the amino end |
| Semax amide or amidate, without N-acetylation | H-MEHFPGP-NH2 | The carboxylic-acid end becomes an amide |
| N-acetyl Semax amidate | Ac-MEHFPGP-NH2 | Both end modifications are present |
Here, Ac- identifies the acetyl modification and -NH2 the terminal amide. The table applies standard peptide notation; a shortened seller title is not proof that the supplied material matches its row. MedChemExpress's specification explicitly describes the dual-modified form as having both N-terminal acetylation and C-terminal amidation. Its product description is evidence of how that supplier identifies its material, not independent proof of clinical benefit. MedChemExpress specification.
Semax acetate is a salt form. N-acetyl Semax has an acetyl group chemically attached to the peptide's amino end. An acetate label therefore does not establish N-acetylation, and neither word establishes C-terminal amidation.
FDA's review treats Semax free base and Semax acetate as distinct bulk drug substances and documents inconsistencies between names, formulas and identifiers in submitted material. Check those fields together. A familiar CAS number printed beside an incompatible sequence needs clarification. FDA review, pages 8 to 10.
For the broader distinction between salt content, purity and peptide quantity, use our peptide acetate versus TFA guide.
Terminal modifications can change enzyme susceptibility and other properties. General peptide chemistry is a reason to investigate a modified form; it cannot establish how much longer a particular Semax product acts in people. GenScript modification guide.
A 2016 study compared Semax with N-terminally acetylated Semax in metal-binding experiments and a cultured human neuroblastoma cell line. Acetylation changed copper coordination, and the acetylated peptide did not reproduce the parent peptide's protection against copper-induced toxicity in that model. This is laboratory evidence that the modification can change behavior. It neither ranks the forms for human cognition nor establishes the effects of adding C-terminal amidation. We reviewed the complete original abstract; the full experimental report was not accessible. Magrì and colleagues, 2016.
A separate 2013 paper concerns the proteolytic stability of Semax acetyl. Its PubMed record has no abstract, and the publisher's full report requires access we did not have. We therefore do not extract a half-life, a stability multiplier or a dosing interval from its title. Shevchenko and colleagues, 2013.
One 2018 study involved 24 healthy volunteers: 14 received intranasal Semax and 10 received placebo. Researchers measured resting-state brain imaging before administration and at 5 and 20 minutes afterward. The original abstract reports a difference in a component of the default mode network. It does not report a demonstrated improvement in everyday memory or work performance, and it does not identify N-acetyl Semax amidate as the intervention. Full methods were unavailable for this review. Lebedeva and colleagues, 2018.
When a listing cites a study, compare the tested molecule, formulation, route, population and measured outcome with the claim. A brain-imaging result for parent Semax cannot establish a superior cognitive effect or safe dose for a differently modified retail product.
The FDA briefing discussed here evaluates Semax free base and acetate for specified proposed compounded uses. It is not an approval of an amidated derivative or a retail product; the document also identifies quality and safety uncertainties. FDA briefing.
Our existing partner Real Peptides lists a product named Semax Amidate. On October 20, 2026, its page described C-terminal amidation and laboratory-only use. That description does not by itself settle whether the N-terminus is also acetylated. We have not independently tested the product or established that its cited biological claims apply to the supplied form.
That is an affiliate link: Biomogging may earn a commission from a purchase. It is included so readers can examine a relevant listing, not as a recommendation for human use.
Before a laboratory procurement decision, ask the supplier:
Keep unresolved identity differences in the procurement record and request clarification before treating two offers as equivalent. Our certificate-of-analysis guide explains how identity, purity and quantity answer separate questions. None of those results establishes a safe personal-use regimen.
Powered by BTST